F&C Asset Management’s Harvard Bioscience HBIO Stock Holding History

F&C Asset Management’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	$3.98M	Sell	83,929 -35,792	-30%	-$1.63M	0.05%	355
2013 Q4	$5.62M	Sell	119,721 -43,138	-26%	-$1.88M	0.07%	317
2013 Q3	$6.49M	Buy	162,859 +4,379	+3%	+$172K	0.08%	289
2013 Q2	$5.65M	Buy	+158,480	New	+$6.07M	0.08%	312

Other funds holding HBIO

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Penbrook Management New York $132M AUM 29.91% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

HSA

Hussman Strategic Advisors Ellicott City, Maryland $463M AUM 16% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

F&C Asset Management's HBIO Position: Q1 2014 in Review

F&C Asset Management reduced its Harvard Bioscience (HBIO) stake by 30% in Q1 2014, selling an estimated $1.63M and leaving 83,929 shares worth $3.98M. The position accounts for 0.05% of the portfolio, ranked #355.

F&C Asset Management first reported a position in HBIO in Q2 2013 and has held it in 4 quarters since. The position peaked at $6.49M in Q3 2013. 74 funds tracked by Wall St. Rank hold HBIO as of Q1 2014.

F&C Asset Management held 83,929 shares of Harvard Bioscience worth $3.98M as of Q1 2014.
F&C Asset Management sold 35,792 Harvard Bioscience shares in Q1 2014, an estimated $1.63M.
Harvard Bioscience made up 0.05% of F&C Asset Management's portfolio in Q1 2014, its #355 holding.
F&C Asset Management first reported a position in Harvard Bioscience in Q2 2013 and has held it in 4 quarters since.
F&C Asset Management's Harvard Bioscience position peaked at $6.49M in Q3 2013.
74 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2014.

Based on F&C Asset Management's 13F filing for Q1 2014, filed 14 May 2014.